The most common AEs with canagliflozin were GMIs (100 mg: 11.8%; 300 mg: 9.2%), hypoglycemia (100 mg: 8.2%; 300 mg: 9.2%; all of these cases were in patients with background insulin or SU), UTIs (100 mg: 4.7%; 300 mg: 7.2%), intravascular volume-related AEs (100 mg: 1.4%; 300 mg: 0.3%), fractures (100 mg: 1.1%; 300 mg: 0%), and polycythemia (100 mg: 0.4%; 300 mg: 1%). Here, INS is linked to polycythemia.